Novavax, Inc. is a pharmaceutical company based in the United States that specializes in vaccine development. With an ESG risk rating score of 27.2, the company is considered to have a medium risk assessment. Novavax is focused on creating innovative vaccine products to prevent a wide range of diseases. The company collaborates with its Swedish subsidiary to develop vaccine candidates for known and emerging disease threats. Novavax believes its technology can be utilized for various infectious diseases. Their business revolves around the development and commercialization of vaccines, with a significant revenue stream coming from Europe.